November 14, is World Diabetes Day! Millions of people globally are living with diabetes, and many of them rely on accurate translations. Here is how Amplexor supports them.
Subscribe to our blog
Globally, there are approximately 425 million adults living with diabetes today. This number is expected to rise to 629 million by the year 2045, which is almost 10% of the global population. There are currently over 46 million people living with diabetes in the U.S. alone. Half of these individuals may not even know they have diabetes.
Glucose monitoring isn’t just important to people living with diabetes. It’s vital and can (and often does) save their lives. Millions of people rely on the timeliness and accuracy of their glucose monitor on a daily basis no matter where in the world they live. Since 2009, Amplexor has partnered with one of the world’s largest manufacturers of glucose monitors to help support those who live with diabetes.
Translation and Localization to Improve Lives
For this global Fortune 500 company, which currently serves 90 countries, development of an app to simplify the task of glucose monitoring was a high priority in 2013. This app would be managed by the patient on their smart device. One thing necessary for the app’s global success was the translation and localization of the app.
The challenge, in addition to localizing the various pieces of the app, was reducing time-to-market by further streamlining the testing process. Before the process was streamlined, it took more than five days to generate localized screenshots for each language.
For their new digital apps project, our customer needed a new plan and process that would help them place the app on the market in the most efficient and high-quality way possible. Ultimately, the content for the new digital app would need to be translated and localized for 26 countries. For a challenge of this size, our customer knew that a certain amount of automation would be necessary.
When it came time to localize the new digital app, Amplexor and our customer had the same goal: to reduce the time it took for the app to go to market in order to better serve users, allowing them more time to focus on their lives and less on their diabetes.
Amplexor examined this issue from all angles, including internal processes at both companies. Efforts were made to streamline translation and localization processes, as well as automate processes for our customer. This resulted in many different processes being automated.
One of the most important changes implemented was the screenshot automation process. This process involved streamlining the way that screenshots were generated. These screenshots were automated and scripted which resulted in the ability to generate screenshots efficiently for all 26 countries. While the initial process took up to five days to complete (per language), now screenshots for multiple locales are returned within one day.
Accurate translations are vital to the survival of those our customers care for on a daily basis. We’re invested in their health and welfare too, and our Amplexor Life Sciences' Diabetes Center of Excellence supports this with best practices across the full product life cycle: from content creation and localization that will meet stiff compliance regulations to innovative mobile app localization. This is our commitment to the 425 million people worldwide living with diabetes.
Published on 14/11/2019 Last updated on 12/11/2020
Kathleen O’Brien is Director of Business Development with Amplexor Life Sciences and a 15-year veteran of the translation industry. Kathleen has a background in linguistics and has held various roles in the translation business: vendor, project and account management, as well as new business development, giving her a unique perspective into both translation operations and how translation impacts the globalization needs of her clients in the pharmaceutical and medical device industries. She proactively collaborates with her life sciences client partners on a daily basis to help them set their localization strategies.